Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Pilot Study of JKB-122 to Assess Liver Tests (ALT) in Autoimmune Hepatitis (AIH) Patients Who Are Refractory or Intolerant to Current Therapies

Next Previous
Trial Profile

A Phase 2, Pilot Study of JKB-122 to Assess Liver Tests (ALT) in Autoimmune Hepatitis (AIH) Patients Who Are Refractory or Intolerant to Current Therapies

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 22 Jul 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs JKB 122 (Primary)
  • Indications Autoimmune hepatitis
  • Focus Therapeutic Use
  • Acronyms JKB-122AIH
  • Sponsors TaiwanJ Pharmaceuticals

Most Recent Events

  • 21 Jan 2019 Results presented in a TaiwanJ Pharmaceuticals Media Release.
  • 21 Jan 2019 Primary endpoint (Changes in ALT in AIH subjects given daily doses of JKB-122) has been met, according to a TaiwanJ Pharmaceuticals media release.
  • 21 Jan 2019 Status changed from active, no longer recruiting to completed, according to a TaiwanJ Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top